Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
COVID-19
Multiple sclerosis
SARS-CoV-2
antibody
disease-modifying treatment
humoral response
seropositivity
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
2
10
2021
medline:
20
11
2021
entrez:
1
10
2021
Statut:
ppublish
Résumé
Knowledge on immunity after SARS-CoV-2 infection in patients with multiple sclerosis (pwMS) and the impact of disease-modifying treatment (DMT) is limited. To evaluate degree, duration and potential predictors of specific humoral immune response in pwMS with prior COVID-19. Anti-SARS-CoV-2 antibody testing was performed in pwMS with PCR-confirmed diagnosis of symptomatic COVID-19 from a nation-wide registry. Predictors of seropositivity were identified by multivariate regression models. In 125 pwMS (mean age = 42.4 years (SD = 12.3 years), 70% female), anti-SARS-CoV-2 antibodies were detected in 76.0% after a median of 5.2 months from positive PCR. Seropositivity rate was significantly lower in patients on IS-DMT (61.4%, Humoral immunity is stable after SARS-CoV-2 infection in MS, but is reduced by immunosuppressive DMT, particularly anti-CD20 monoclonal antibodies. This provides important evidence for advising pwMS as well as for planning and prioritizing vaccination.
Sections du résumé
BACKGROUND
Knowledge on immunity after SARS-CoV-2 infection in patients with multiple sclerosis (pwMS) and the impact of disease-modifying treatment (DMT) is limited.
OBJECTIVE
To evaluate degree, duration and potential predictors of specific humoral immune response in pwMS with prior COVID-19.
METHODS
Anti-SARS-CoV-2 antibody testing was performed in pwMS with PCR-confirmed diagnosis of symptomatic COVID-19 from a nation-wide registry. Predictors of seropositivity were identified by multivariate regression models.
RESULTS
In 125 pwMS (mean age = 42.4 years (SD = 12.3 years), 70% female), anti-SARS-CoV-2 antibodies were detected in 76.0% after a median of 5.2 months from positive PCR. Seropositivity rate was significantly lower in patients on IS-DMT (61.4%,
CONCLUSIONS
Humoral immunity is stable after SARS-CoV-2 infection in MS, but is reduced by immunosuppressive DMT, particularly anti-CD20 monoclonal antibodies. This provides important evidence for advising pwMS as well as for planning and prioritizing vaccination.
Identifiants
pubmed: 34595968
doi: 10.1177/13524585211049391
pmc: PMC8597187
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2209-2218Références
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835
pubmed: 34035836
Eur J Neurol. 2021 Oct;28(10):3384-3395
pubmed: 33340215
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
Mult Scler Relat Disord. 2021 Feb;48:102698
pubmed: 33385826
Mult Scler Relat Disord. 2021 May;50:102800
pubmed: 33578206
Neurology. 2020 Jun 2;94(22):949-952
pubmed: 32241953
Neurol Neuroimmunol Neuroinflamm. 2020 May 15;7(4):
pubmed: 32414755
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Wien Klin Wochenschr. 2021 Apr;133(7-8):351-358
pubmed: 33315138
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Clin Exp Immunol. 2020 Nov;202(2):149-161
pubmed: 32671831
J Clin Med. 2020 Dec 16;9(12):
pubmed: 33339436
Eur J Neurol. 2021 Oct;28(10):3369-3374
pubmed: 32978860
Mult Scler Relat Disord. 2021 May;50:102793
pubmed: 33588315
JAMA Neurol. 2021 Jul 1;78(7):880-882
pubmed: 33929488
Sustain Prod Consum. 2021 Apr;26:343-359
pubmed: 33072833
Mult Scler. 2022 Jun;28(7):1034-1040
pubmed: 34328824
Mult Scler Relat Disord. 2021 Jul;52:103014
pubmed: 34000684
PLoS One. 2021 Jul 27;16(7):e0255316
pubmed: 34314457
Mult Scler. 2022 Jan;28(1):165-167
pubmed: 34387536
Clin Microbiol Infect. 2021 Sep;27(9):1349.e1-1349.e6
pubmed: 33975009